Ricola earns the trust of Switzerland
Ricola has been voted the most trustworthy brand in Switzerland. The manufacturer of herbal candy, which is based in the Basel Area, previously won this award in 2017.
Production of Ricola's herbal candy in the Basel Area (img: Ricola)
Promarca, the Swiss Branded Goods Association, has issued a press release containing information in connection with the survey conducted by Havas Schweiz and Management Tools Research AG examining the most trustworthy brands in Switzerland. In this context, a study that polled 3,213 respondents from the German-speaking region of Switzerland and western Switzerland was also conducted, from which Ricola emerged victorious from a total of 421 Promarca member brands. The world-renowned Basel-based manufacturer of herbal candy was previously named winner of the Promarca Brand of the Year Award in 2017, and has now been able to secure a repeat of this success.
The Brand Predictor Survey conducted by Havas Schweiz and Management Tools Research AG will predict the future, explains Andreas Logk, CEO of Management Tools Research, in the press release. “This clearly differentiates the model from other market tools for which the assessments are based on more one-dimensional criteria and previous success”, he stated. According to Nathalie Diethelm, CEO of Havas Worldwide Switzerland, Ricola was one of the biggest winners among all 421 brands. She explained: “Ricola impressed with a high level of consistency in its brand promises. It has continually built upon its strengths and has successfully captured the zeitgeist and consumer preferences with its product developments”.
Judging by his comments in the press release, Thomas P. Meier, CEO of the Ricola Group, which is based in Laufen in the canton of Basel-Landschaft, was clearly delighted to receive this award: “We are proud that our customers are happy with the quality of our products and enthused by our performance promise”.
You may also be interested in
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More